Sunil Verma

17.6k total citations · 5 hit papers
164 papers, 10.6k citations indexed

About

Sunil Verma is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sunil Verma has authored 164 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 122 papers in Oncology, 71 papers in Pulmonary and Respiratory Medicine and 42 papers in Cancer Research. Recurrent topics in Sunil Verma's work include HER2/EGFR in Cancer Research (59 papers), Cancer Treatment and Pharmacology (50 papers) and Advanced Breast Cancer Therapies (49 papers). Sunil Verma is often cited by papers focused on HER2/EGFR in Cancer Research (59 papers), Cancer Treatment and Pharmacology (50 papers) and Advanced Breast Cancer Therapies (49 papers). Sunil Verma collaborates with scholars based in Canada, United States and Germany. Sunil Verma's co-authors include Ian E. Krop, Mark D. Pegram, Véronique Dièras, David Miles, Luca Gianni, Manfred Welslau, Nadia Harbeck, Kim T. Blackwell, Jungsil Ro and Nicholas C. Turner and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Sunil Verma

158 papers receiving 10.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

2012 2.7k citations Sunil Verma, David Miles et al. New England Journal of Medicine profile →
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

2016 1.2k citations Massimo Cristofanilli, Nicholas C. Turner et al. The Lancet Oncology profile →
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

2015 1.1k citations Nicholas C. Turner, Jungsil Ro et al. New England Journal of Medicine profile →
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

2018 777 citations Nicholas C. Turner, Dennis J. Slamon et al. New England Journal of Medicine profile →
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

2017 465 citations Véronique Dièras, David Miles et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sunil Verma Canada	39	7.8k	5.1k	2.5k	2.1k	1.7k	164	10.6k
Jean-Marc Ferrero France	41	6.4k 0.8×	4.0k 0.8×	3.0k 1.2×	2.0k 1.0×	1.8k 1.1×	207	9.6k
Kimberly Blackwell United States	50	6.0k 0.8×	2.4k 0.5×	1.9k 0.8×	2.0k 0.9×	2.1k 1.2×	138	9.2k
Sara A. Hurvitz United States	53	8.2k 1.0×	4.2k 0.8×	2.6k 1.0×	1.7k 0.8×	3.2k 1.9×	375	11.0k
Andrew D. Seidman United States	50	8.1k 1.0×	2.5k 0.5×	2.2k 0.9×	2.0k 1.0×	2.2k 1.2×	211	11.1k
Maura N. Dickler United States	47	6.4k 0.8×	3.3k 0.6×	2.8k 1.1×	952 0.5×	3.4k 2.0×	166	10.5k
Tadeusz Pieńkowski Poland	39	9.6k 1.2×	2.5k 0.5×	3.8k 1.5×	3.3k 1.6×	2.0k 1.2×	129	12.0k
Sara M. Tolaney United States	54	11.6k 1.5×	5.3k 1.0×	3.7k 1.5×	2.0k 1.0×	2.8k 1.6×	502	14.8k
Joohyuk Sohn South Korea	44	7.9k 1.0×	5.6k 1.1×	3.3k 1.3×	650 0.3×	1.8k 1.1×	303	10.9k
Carey K. Anders United States	45	5.4k 0.7×	2.8k 0.5×	2.6k 1.0×	672 0.3×	2.0k 1.2×	211	8.7k
Young‐Hyuck Im South Korea	51	8.7k 1.1×	3.7k 0.7×	3.8k 1.5×	2.5k 1.2×	2.9k 1.7×	270	12.4k

Countries citing papers authored by Sunil Verma

Since Specialization

Citations

This map shows the geographic impact of Sunil Verma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sunil Verma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sunil Verma more than expected).

Fields of papers citing papers by Sunil Verma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sunil Verma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sunil Verma. The network helps show where Sunil Verma may publish in the future.

Co-authorship network of co-authors of Sunil Verma

This figure shows the co-authorship network connecting the top 25 collaborators of Sunil Verma. A scholar is included among the top collaborators of Sunil Verma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sunil Verma. Sunil Verma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xiao, Ting, Sunil Verma, Gabriel Boldt, et al.. (2023). Efficacy and Safety of Immune Checkpoint Inhibitors (ICI) in Resectable Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis. International Journal of Radiation Oncology*Biology*Physics. 118(1). e6–e6. 1 indexed citations

Verma, Sunil, et al.. (2020). Comparative study analyzing efficacy and safety of sitagliptin with metformin versus glimepiride with metformin on patients of type-2 diabetes mellitus. Indian Journal of Pharmacy and Pharmacology. 7(1). 26–33.

Baselga, José, Susan Dent, Javier Cortés, et al.. (2018). Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. Journal of Clinical Oncology. 36(18_suppl). LBA1006–LBA1006. 105 indexed citations

Joy, Anil A., et al.. (2018). Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines. Current Oncology. 25(11). 131–141. 32 indexed citations

Verma, Sunil, Joyce O’Shaughnessy, Howard A. Burris, et al.. (2017). Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.. Journal of Clinical Oncology. 35(15_suppl). 1020–1020. 9 indexed citations

Loibl, Sibylle, Nicholas C. Turner, Jungsil Ro, et al.. (2017). Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. The Oncologist. 22(9). 1028–1038. 99 indexed citations

Dièras, Véronique, Nadia Harbeck, Anil A. Joy, et al.. (2017). PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L). Annals of Oncology. 28. v96–v96. 6 indexed citations

Schmid, Peter, Jonas Bergh, Lajos Pusztai, et al.. (2017). KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). Annals of Oncology. 28. v72–v72. 5 indexed citations

Thomas, Scott, Robert C. Doebele, David R. Spigel, et al.. (2017). A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts. Annals of Oncology. 28. ii42–ii43. 3 indexed citations

10.

Baselga, José, Gail D. Lewis Phillips, Sunil Verma, et al.. (2016). Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research. 22(15). 3755–3763. 150 indexed citations

11.

Cristofanilli, Massimo, Nicholas C. Turner, Igor Bondarenko, et al.. (2016). Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet Oncology. 17(4). 425–439. 1247 indexed citations breakdown →

12.

Nixon, Nancy & Sunil Verma. (2016). A Value-Based Approach to Treatment of HER2-Positive Breast Cancer: Examining the Evidence. American Society of Clinical Oncology Educational Book. 36. e56–e63. 6 indexed citations

13.

Gong, Inna Y., Sunil Verma, Andrew T. Yan, et al.. (2016). Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. Breast Cancer Research and Treatment. 157(3). 535–544. 22 indexed citations

14.

Chow, Ronald, Natalie Pulenzas, Liying Zhang, et al.. (2015). Quality of life and symptom burden in patients with breast cancer treated with mastectomy and lumpectomy. Supportive Care in Cancer. 24(5). 2191–2199. 31 indexed citations

15.

Maralani, Pejman, et al.. (2014). Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases. BMJ Case Reports. 2014. bcr2014205680–bcr2014205680. 23 indexed citations

16.

Hirsh, Vera, Normand Blais, Ronald L. Burkes, Sunil Verma, & Kenneth Croitoru. (2014). Management of Diarrhea Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Current Oncology. 21(6). 329–336. 81 indexed citations

17.

Verma, Sunil, Anil A. Joy, Daniel Rayson, et al.. (2013). HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer. The Oncologist. 18(11). 1153–1166. 11 indexed citations

18.

Verma, Sunil, David Miles, Luca Gianni, et al.. (2012). Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 367(19). 1783–1791. 2665 indexed citations breakdown →

19.

Gelmon, Karen A., Rebecca Dent, John R. Mackey, et al.. (2012). Targeting triple-negative breast cancer: optimising therapeutic outcomes. Annals of Oncology. 23(9). 2223–2234. 141 indexed citations

20.

Verma, Sunil. (2008). Going beyond efficacy: supportive care and addressing the toxicity of systemic therapy. Current Oncology. 15(11). 3–3. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact